Emactuzumab, a humanized immunoglobulin G1 monoclonal antibody, targets the CSF-1 receptor and inhibits macrophages in tumor tissue.

T-cell activation involves two phases, enabling a more precise immune response. This insight may boost cancer immunotherapy effectiveness. A research team led by Wolfgang Kastenmüller and Georg ...

An international collaboration between four scientists from Mainz, Valencia, Madrid, and Zurich has published new research in ...

The first patient with small cell lung cancer has been dosed in a phase 1/2 trial investigating first-line iadademstat plus immune checkpoint inhibitors. The first patient with small cell lung cancer ...

BeiGene has made the decision to end the clinical development program for ociperlimab (BGB-A1217) for the treatment of lung cancer.

The phase 1 clinical trial will assess CLN-978 in patients with ... “CLN-978 is the only CD19-targeting T cell engager advancing a global regulatory development plan that includes a US FDA-cleared IND ...

Scientists could reshape cancer treatment by helping powerful drugs work better in the body by exploiting a surface protein called CD36 that helps pull substances into cells. This dramatically ...

Purpose: The pharmacology, pharmacokinetics, clinical efficacy, and safety of rasagiline are reviewed. Summary: Rasagiline is a novel, investigational propargylamine that irreversibly and ...

Department of Neurosurgery, Neurological Institute, Taichung Veterans General Hospital, Taichung 407219, Taiwan R.O.C. Department of Physical Therapy, Hung Kuang ...